Exclusive licensing agreement with Elegen and acquisition of SynPlexity strengthen gene synthesis capabilities,

与 Elegen 的独家许可协议以及对 SynPlexity 的收购增强了基因合成能力，

expand high-throughput discovery workflows, and position GENEWIZ for long-term growth

扩展高通量发现工作流程，并为GENEWIZ的长期增长奠定基础

BURLINGTON, Mass.

马萨诸塞州伯灵顿

,

，

Oct. 30, 2026

2026年10月30日

/PRNewswire/ -- Azenta, Inc. (Nasdaq:

/美通社/ -- Azenta, Inc.（纳斯达克股票代码：

AZTA

AZTA

) today announced strategic investments to advance the next phase of growth for its GENEWIZ business. Building on its trusted brand, scientific expertise, global commercial engine, and operational infrastructure, Azenta is expanding its capabilities through an exclusive licensing agreement with Elegen Corp., a developer of advanced cell-free DNA manufacturing technology, and the acquisition of SynPlexity Inc., a synthetic biology company providing high-throughput gene libraries for biological discovery..

）今日宣布进行战略投资，以推动其 GENEWIZ 业务进入下一增长阶段。依托其值得信赖的品牌、科学专业知识、全球商业化引擎和运营基础设施，Azenta 正通过与先进无细胞 DNA 制造技术开发商 Elegen Corp. 签订独家许可协议，以及收购为生物发现提供高通量基因文库的合成生物学公司 SynPlexity Inc.，来扩展其业务能力。

The license agreement with Elegen brings into the GENEWIZ portfolio an innovative cell-free DNA synthesis platform designed to improve DNA quality, delivery speed, and manufacturing scalability. Its capabilities include sequence-verified DNA constructs and templates to simplify preparation for downstream experiments, including antibody discovery.

与Elegen达成的许可协议为GENEWIZ的产品组合引入了一种创新的无细胞DNA合成平台，旨在提高DNA质量、交付速度和制造可扩展性。该平台的能力包括提供经序列验证的DNA构建体和模板，以简化下游实验（包括抗体发现）的准备工作。

The compact production workflows also enable regional capacity to be added close to customers to respond to demand as needed..

紧凑的生产工作流程还使得能够在靠近客户的地方增加区域产能，以按需响应需求。

Azenta has also acquired SynPlexity, adding pooled gene assembly technology that provides thousands of full-length gene variants in a single library. These capabilities address the increasing scale of biological design by enabling researchers to efficiently build and test large numbers of candidates, including AI-generated designs..

Azenta 还收购了 SynPlexity，引入了池化基因组装技术，可在单个文库中提供数千种全长基因变体。这些能力使研究人员能够高效构建和测试大量候选方案（包括人工智能生成的设计），从而应对生物设计日益扩大的规模需求。

'These strategic investments strengthen the competitive position of GENEWIZ by expanding the products and capabilities we can bring to customers and are key to accelerating our growth,' said Trey Martin, President, Multiomics at Azenta. 'By combining these advanced technologies with our global infrastructure and existing gene-to-antibody portfolio, we are building a differentiated platform poised to accelerate the next era of biologics discovery and development.'.

“这些战略性投资通过扩展我们能够为顾客提供的产品和能力，增强了GENEWIZ的竞争力，并且对加速我们的增长至关重要。”Azenta多组学总裁Trey Martin表示，“通过将这些先进技术与我们的全球基础设施以及现有的从基因到抗体的产品组合相结合，我们正在构建一个具有差异化的平台，有望推动生物制剂发现和开发的下一个时代。”

Since its founding in New Jersey in 1999, GENEWIZ has built a global sequencing and gene synthesis business grounded in scientific expertise, customer focus, and operational excellence. These investments complement and extend that foundation into higher-growth applications across synthetic biology, protein engineering, and AI-enabled drug discovery..

自1999年在新泽西州成立以来，GENEWIZ已建立起以科学专长、客户聚焦和卓越运营为基础的全球测序与基因合成业务。这些投资进一步巩固并拓展了这一基础，延伸至合成生物学、蛋白质工程以及人工智能赋能的药物发现等高增长应用领域。

Additional details will be provided during Azenta's fourth quarter fiscal 2026 earnings call.

更多细节将在Azenta 2026财年第四季度的财报电话会议上提供。

About Azenta Life Sciences

关于Azenta生命科学

Azenta, Inc. (Nasdaq:

Azenta, Inc.（纳斯达克：

AZTA

AZTA

) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally.

）是全球领先的生命科学解决方案提供商，助力世界各地的生命科学组织更快地将具有重大影响的突破成果和疗法推向市场。Azenta 为全球顶尖的制药、生物技术、学术和医疗保健机构提供全套可靠的冷链样本管理解决方案及多组学服务，涵盖药物开发、临床研究和先进细胞治疗等领域。

Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey..

我们的全球团队通过旗下行业领先的品牌（包括 GENEWIZ、FluidX、Ziath、4titude、Limfinity、Freezer Pro 和 Barkey）提供并支持这些产品和服务。

Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit

Azenta 总部位于马萨诸塞州伯灵顿，业务遍及北美、欧洲和亚洲。如需更多信息，请访问

www.azenta.com

www.azenta.com

About Elegen

关于 Elegen

Elegen uses proprietary cell-free technologies to build longer, higher-quality DNA on a faster timeline for agricultural, chemical, healthcare, and pharma industries.

Elegen 利用专有的无细胞技术，在更短的时间内为农业、化工、医疗保健和制药行业构建更长、更高质量的 DNA。

About SynPlexity

关于 SynPlexity

SynPlexity is a DNA assembly technology company providing products and services centered on large, multiplexed libraries for functional screening, drug discovery, therapeutics, and other applications.

SynPlexity 是一家 DNA 组装技术公司，提供以用于功能筛选、药物发现、治疗及其他应用的大型多重化文库为核心的产品与服务。

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性陈述的警示说明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Azenta's plans to develop, integrate, manufacture and commercialize products using the licensed and acquired technologies and the anticipated benefits of the transactions, including expected improvements in gene synthesis capabilities, expansion of the GENEWIZ offerings and markets, customer adoption and demand, and financial, operational and strategic benefits.

本新闻稿包含1995年《私人证券诉讼改革法》所定义的“前瞻性陈述”，包括有关Azenta计划利用授权及收购技术开发、整合、制造和商业化产品，以及交易预期带来的益处的陈述，其中包括基因合成能力的预期提升、GENEWIZ产品与市场的扩张、客户采用率与需求增长，以及在财务、运营和战略方面的益处。

Actual results could differ materially from those expressed or implied due to risks and uncertainties, including Azenta's ability to transfer, validate, integrate and scale the technologies, achieve expected technical and commercial performance, protect relevant intellectual property and realize the anticipated benefits, as well as the risks described under 'Risk Factors' in Azenta's Annual Report on Form 10-K for the fiscal year ended September 30, 2025, as updated or supplemented by subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission.

由于各种风险和不确定性，实际结果可能与明示或暗示的结果存在重大差异。这些风险和不确定性包括：Azenta 转移、验证、整合和扩展技术的能力，实现预期技术和商业表现的能力，保护相关知识产权的能力，以及实现预期收益的能力；此外还包括 Azenta 截至 2025 年 9 月 30 日财政年度的 10-K 表格年度报告中“风险因素”部分所述的风险，该报告已由后续的 10-Q 表格季度报告及其他向美国证券交易委员会提交的文件进行更新或补充。

Forward-looking statements speak only as of the date made, and Azenta undertakes no obligation to update them except as required by law..

前瞻性陈述仅反映其作出之日的情况，除法律要求外，Azenta 不承担更新这些陈述的义务。

INVESTOR CONTACT for Azenta Life Sciences:

Azenta Life Sciences 投资者联系人：

Yvonne Perron

伊冯·佩龙

Vice President, Financial Planning & Analysis, and Investor Relations

副总裁，财务规划与分析及投资者关系

[email protected]

[email protected]

Maria Isabel Cuartas

玛丽亚·伊莎贝尔·夸尔塔斯

Manager, Investor Relations

投资者关系经理

[email protected]

[email protected]

SOURCE Azenta

来源：Azenta